{"doi":"10.1002/hon.70094_414","title":"414 | CT‐BASED BODY COMPOSITION IN PATIENTS WITH FOLLICULAR LYMPHOMA COMPARED WITH THE GENERAL POPULATION, AND ASSOCIATION BETWEEN BODY COMPOSITION AND LYMPHOMA OUTCOMES","abstract":"J. Ford, L. Mantz, F. Fintelmann, and J. D. Soumerai equally contributing author. Introduction: The body composition (BC; skeletal muscle, subcutaneous and visceral adipose tissue) of patients (pts) with grade 1–3a/classic follicular lymphoma (cFL) is not defined. Given the long natural history of cFL and previous studies suggesting associations between body composition and lymphoma outcomes, we hypothesized that we would observe changes in BC over time between pts with cFL compared with the general population and that sex-specific BC changes would be associated with cFL outcomes. Methods: We identified 677 consecutive pts with cFL at Mass General Hospital from 1/2015 to 7/2022 using an IRB-approved registry, of whom 457 had computed tomography (CT) images available from initial diagnosis (Dx) for BC analyses (Dx Cohort), and 295 who received first-line systemic therapy (1LTx) for cFL and had pre-1LTx CT imaging for BC analysis (1LTx Cohort). We performed BC analysis (3rd lumbar vertebral level) using a validated and fully automated deep learning image analysis pipeline with manual quality control. Skeletal muscle index (SMI), and subcutaneous (SATI), visceral (VATI) and total adiposity indices (TATI), were quantified, and age-/sex-adjusted index z-scores (z-SMI, z-SATI, z-VATI, and z-TATI) were calculated using the Framingham Heart Study reference cohort. Time to Next Therapy (TTNT) was calculated from start of 1LTx until second-line treatment or death due to lymphoma. Cox regression models estimating hazard ratios (HR) and 95% confidence intervals (CI) for TTNT were adjusted for stage, nodal sites, hemoglobin, LDH (and age and sex in non-z-scores), with or without > 10% weight loss, and were grouped by sex. Results: Of 457 pts, median age was 61 (IQR, 52–70), 51% were women, 26% and 23% were FLIPI medium and high risk, 65% received 1LTx (70% chemoimmunotherapy, 25% CD20 antibody alone, and 5% other), and median follow-up was 72.1 mo. At Dx and Pre-1LTx, and for men and women, SMI, SATI, VATI and TATI were all lower than in the general population (Table 1). Among pts who were recommended initial surveillance prior to 1LTx, we observed statistically significant reductions in z-SATI, z-VATI, and z-TATI from Dx to Pre-1LTx in women, and in SMI and z-SMI in men. Among women who received 1LTx, greater VATI and z-VATI pre-1LTx were associated with prolonged TTNT, and these effects persisted after adjusting for > 10% pre-1LTx weight loss (Table 1). Among men who received 1LTx, greater SMI pre-1LTx was associated with prolonged TTNT, but not after adjusting for weight loss. Conclusion: Skeletal muscle, subcutaneous and visceral adipose tissue measures were all significantly lower among pts with cFL at diagnosis when compared to an age- and sex-matched general population and further reduced in a sex-dependent manner prior to 1LTx (greater reduction in adipose tissue for women and skeletal muscle for men). Among pts who received 1LTx, greater VATI and SMI at pre-1LTx were associated with prolonged TTNT for women and men, respectively. Research funding declaration: J.D.S. is supported by the National Cancer Institute of the National Institutes of Health under award number [K08CA270202]. This work was made possible through the MGH Lymphoma Translational Research and Biobanking Collaborative supported by the Scott Nathan and Laura DeBonis Fund for Clinical Research (JSA). Keywords: non-Hodgkin; other; other imaging and early detection No potential sources of conflict of interest.","journal":"Hematological Oncology","year":2025,"id":568521,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9503,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1219490,"name":"Lea Mantz","orcid":"0000-0003-0998-8812","position":1,"is_corresponding":false},{"id":250460,"name":"Robert Redd","orcid":"0000-0002-1329-5288","position":2,"is_corresponding":false},{"id":648188,"name":"Matthew Lei","orcid":"0000-0001-5348-6065","position":3,"is_corresponding":false},{"id":258324,"name":"Jeremy S. Abramson","orcid":"0000-0001-8467-9257","position":4,"is_corresponding":false},{"id":1472791,"name":"J. Barnes","orcid":"0000-0001-5717-5336","position":5,"is_corresponding":false},{"id":1241841,"name":"Ronald W. Takvorian","orcid":null,"position":6,"is_corresponding":false},{"id":844354,"name":"Ephraim P. Hochberg","orcid":"0000-0001-9050-7208","position":7,"is_corresponding":false},{"id":1473360,"name":"Paul C. Johnson","orcid":null,"position":8,"is_corresponding":false},{"id":289515,"name":"J. Erika Haydu","orcid":"0000-0003-2463-0560","position":9,"is_corresponding":false},{"id":1225234,"name":"R Nemec","orcid":"0009-0005-7837-1279","position":10,"is_corresponding":false},{"id":544474,"name":"C. Cho","orcid":null,"position":11,"is_corresponding":false},{"id":1472792,"name":"J. M. Lynch","orcid":"0000-0001-9761-5180","position":12,"is_corresponding":false},{"id":1285817,"name":"Emily S. Patterson","orcid":"0000-0002-4514-2075","position":13,"is_corresponding":false},{"id":1473361,"name":"K Thorp","orcid":null,"position":14,"is_corresponding":false},{"id":1447501,"name":"Maryanne M. Sherburne","orcid":null,"position":15,"is_corresponding":false},{"id":635721,"name":"Brianne McGree","orcid":null,"position":16,"is_corresponding":false},{"id":401578,"name":"Florian J. Fintelmann","orcid":"0000-0002-0119-3903","position":17,"is_corresponding":false},{"id":232465,"name":"Jacob D. Soumerai","orcid":"0000-0002-3062-6819","position":18,"is_corresponding":false},{"id":1225233,"name":"Josie Ford","orcid":"0009-0004-7612-3258","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:56:52.212268Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}